Evaluation in 3 moNths Duration of nEointimAl coVerAge After zOtaRolimus-Eluting Stent Implantation by Optical Coherence Tomography (ENDEAVOR OCT).

Trial Profile

Evaluation in 3 moNths Duration of nEointimAl coVerAge After zOtaRolimus-Eluting Stent Implantation by Optical Coherence Tomography (ENDEAVOR OCT).

Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 09 Dec 2009

At a glance

  • Drugs Zotarolimus (Primary)
  • Indications Coronary artery disease; Coronary artery restenosis
  • Focus Adverse reactions; Registrational
  • Acronyms ENDEAVOR OCT
  • Most Recent Events

    • 28 Jan 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top